On February 4, 2025, Bionano Genomics suspended its previous stock sales agreement and entered a new At The Market Offering Agreement with H.C. Wainwright to potentially sell up to $75 million in shares. The new agreement allows sales at the company's discretion, with a commission of 3% on proceeds.